SEC Comment Letter for AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — May 8, 2018

AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: May 8, 2018 · CIK: 0001385818 · Accession: 0000000000-18-014266

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38247

Date

May 8, 2018

Author

Joshua R. Disbrow

Form

UPLOAD

Company

AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)

Letter

May 8, 2018 Joshua R. Disbrow Chairman and Chief Executive Officer Aytu BioScience, Inc. 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Re:Aytu BioScience, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 27, 2018 File No. 001-38247 Dear Mr. Disbrow: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Marcelle S. Balcombe, Esq.

Show Raw Text

May 8, 2018
Joshua R. Disbrow
Chairman and Chief Executive Officer
Aytu BioScience, Inc.
373 Inverness Parkway, Suite 206
Englewood, Colorado 80112
Re:Aytu BioScience, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed April 27, 2018
File No. 001-38247
Dear Mr. Disbrow:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       Marcelle S. Balcombe, Esq.

SecProbe.io